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ABSTRACT 
Background Allogeneic stem cell transplantation (HSCT) is the only curative treatment in 
myelodysplastic syndromes (MDS). Azacitidine (AZA) is increasingly used prior to HSCT, 
however in Europe it is only approved for patients who are not eligible for HSCT. 
Patients and Methods We conducted a phase II multicenter study to prospectively 
evaluate the feasibility of HSCT after treatment with AZA in 70 patients with a 
myelodysplastic syndrome (MDS), 19 with acute myeloid leukemia (AML), and 8 with 
chronic myelomonocytic leukemia (CMML). After a median of 4 cycles (range 1-11): 24% 
of patients achieved complete remission, 14% partial remission, 8% hematologic 
improvement, 32% had stable and 22% progressive disease. Ten patients discontinued 
treatment before the planned 4 cycles, due to an adverse event in 9 cases. 
Results A HSC donor was identified in 73 patients, and HSCT was performed in 54 
patients (74% of patients with a donor). Main reasons for turning down HSCT were lack of 
a donor, an adverse event, or progressive disease (9, 12 and 16 patients, respectively). At 
a median follow-up of 20.5 months from enrolment, response to AZA was the only 
independent prognostic factor for survival. Compared to baseline assessment, AZA 
treatment did not affect patients’ comorbidities at HSCT: the HCT-CI remained stable in 
62% patients, and worsened or improved in 23% and 15% of patients, respectively. 
Conclusions Our study shows that HSCT is feasible in the majority of patients with HR-
MDS/AML/CMML-2 after AZA treatment. As matched unrelated donor was the most 
frequent source of donor cells, the time between diagnosis and HSCT needed for donor 
search could be “bridged” using azacitidine. These data show that AZA prior to HSCT 
could be a better option than intensive chemotherapy in higher-risk MDS.  
 
The trial has been registered with the EudraCT number 2010-019673-1. 
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KEY MESSAGE 
In this study, we prospectively evaluated patient outcome from the time of HR-MDS/AML, 
diagnosis through azacitidine induction, followed by HSCT. We show that HSCT is feasible 
after azacitidine in 74% of HR-MDS/AML patients with a stem cell donor. In addition, AZA 
did not significantly impact patient comorbidities, but improved the disease status, which 
was independently associated to improved survival after HSCT.   
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INTRODUCTION 
The prognosis of higher-risk MDS, including IPSS intermediate-2/high risks1 or high and 
very-high risks according to the IPSS-R2, closely resembles that of elderly AML, with a 
dismal predicted survival of one year or less. In this disease, HSCT remains the only 
curative option and is generally recommended for patients who are candidates to high-
intensity treatment (NCCN Guidelines Version 1.2016).  
After HSCT, other factors predicting survival in MDS are patient characteristics, as age 
and Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI)3, and disease-related 
factors, including prior duration of MDS, iron overload, karyotype, IPSS-R, and disease 
status at the time of HSCT conditioning.4-5 The issue of donor selection is evolving and the 
increasing use of haplo-identical siblings has improved donor availability in recent years.6 
In parallel, the application of reduced-intensity conditioning (RIC) regimens has contributed 
to reduce transplant-related mortality, but at the cost of increasing rates of disease 
relapse.7 
In this context, pre-transplant therapy represents a relevant issue in MDS, since 
conventional chemotherapy is associated with a high number of complications, besides 
low complete remission (CR) and high relapse rates.8 In this regard, retrospective studies 
have shown similar survival outcomes in patients treated with intensive chemotherapy 
prior to HSCT compared to those transplanted upfront.9-10 The EBMT group reported that, 
out of 341 evaluable patients including 244 MDS, only 16% finally underwent HSCT.11 
Similarly, a prospective study from the MD Anderson Cancer Research Center reported 
that less than 10% patients with HR-MDS or AML underwent HSCT after standard 
induction chemotherapy.12  
Treatment outcomes in HR-MDS have significantly improved after the introduction of 
hypomethylating treatment (HMT), in particular azacitidine (AZA).13 CR rates of 15-20% 
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after AZA treatment have been reported in prospective studies and confirmed in “real-life” 
patient cohorts, but the overall response rate, including PR and HI, reaches up to 50%.13,14 
In contrast with intensive chemotherapy, treatment complications are relatively low, with a 
vast majority of patients able to complete the 4-6 cycles necessary to obtain most of 
responses.  
In the present multicenter study, we prospectively assessed the feasibility of HSCT in a 
large series of patients with HR-MDS, chronic myelomonocytic leukemia (CMML)-2, or 
AML with 20-30% blasts, following 4-6 standard courses of AZA, given with the purpose of 
reducing the disease burden, delaying disease progression and bridging the time to 
transplant.  
 
PATIENTS AND METHODS 
 
This prospective phase II non-randomized trial was conducted in 20 Hematology centers 
affiliated to the GITMO (Gruppo Italiano Trapianto di Midollo osseo e Terapie Cellulari) 
and/or GIMEMA (Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto) networks. 
The primary end-point of the study was the proportion of patients with HR-MDS, classified 
according to IPSS1, able to perform HSCT after treatment with AZA. Further details 
regarding the study design are available in the Supplementary Materials, Online. The 
study was conducted in agreement with the Declaration of Helsinki, the ICH Harmonized 
Tripartite Guideline for Good Clinical Practice principles and procedures, and the Italian 
legislation requirements. The trial was approved by the ethic committees of all participating 
centers. All patients provided written informed consent before inclusion. 
 
Treatment and Outcomes 
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Eligible patients received AZA 75mg/sqm/day subcutaneously for 7 days every 28 days for 
at least 4 cycles, followed by HSCT if a suitable sibling or unrelated donor was available. A 
minimum of 4 AZA cycles had to be given; however up to a total of 12 cycles were 
allowed. Pre-HSCT conditioning regimen was to be administered 4 to 8 weeks after the 
last AZA administration. Patients without a donor or unsuitable to or denying consent for 
HSCT, were allowed to continue AZA until a response persisted. Patients were followed 
and events recorded until progression to AML and/or death or to last available follow-up. 
Response was evaluated by BM aspirate and/or biopsy and cytogenetic analysis every 4 
cycles of AZA, and before HSCT. The HCT-CI score was assessed at treatment start and 
before HSCT to identify three patient groups (low-risk: 0, intermediate: 1-2, high: >3).3  
The primary endpoint was the proportion of patients who indeed underwent HSCT after 
bridge with AZA. Secondary endpoints were overall response rate (ORR) to AZA, safety of 
AZA, overall and disease-free survival (OS, DFS), transplant related mortality (TRM), and 
progression-free survival (PFS). Matched sibling or unrelated HLA 8/10 to 10/10 donor 
were allowed. Conditioning regimen before HSCT, and GVHD prophylaxis were according 
to the policy of the participating institutions.  
This study was designed as a Simon optimal two-Stage Phase II clinical trial15 to test the 
null hypothesis that P<0.180 versus the alternative that P>0.300 had an expected sample 
size of 50.78 and a probability of early termination of 0.681. Details on the statistical 
analysis are reported in Supplementary materials, online.  
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RESULTS 
 
Feasibility of HSCT after AZA-bridge 
From October 2010 to September 2014, 102 transplant-eligible patients were screened for 
enrolment into the study (Figure 1). Five patients did not enter the study due to rapid 
disease progression (n=2) or consent withdrawal (n=3). AZA was started at a median of 
0.9 months (range 0-105 months) from diagnosis of higher-risk MDS, CMML or AML and 
at 0.4 months (range: 0-2.3) from registration in 97 patients (34 females, 63 males), with a 
median age of 59 years (range 21-66.5 years). Eleven patients had a prior diagnosis of 
lower-risk MDS. The main patient characteristics are shown in Supplementary Table 1. 
MDS 2016 WHO classification16 and risk stratification, according to IPSS, WPSS and 
IPSS-R was re-assessed for all patients with available information.  
Treatment was discontinued in 10 patients after a median of 2 cycles (range 1-3), mostly 
due to an adverse event (n=6, Figure 1). After 4 AZA cycles, CR was achieved in 21 
patients (24%), partial remission (PR) in 12 patients (14%), hematologic improvement (HI) 
in 7 (8%), while the disease was considered stable in 28 (SD: 32%), and progressive in 19 
patients (PD: 22%). Donor search was started at a median of 0.1 months from protocol 
inclusion (range -97 to +4.6 months), and was prematurely terminated due to progressive 
disease in 4 patients. A HSC donor was identified in 73 of 93 patients (78.5%) after a 
median of 3.4 months from AZA start (range 0.9-11.8 months). 
Thirty-three patients did not undergo HSCT, due to lack of a suitable SC donor (n=9), PD 
(n=16), adverse event (n=3), consent withdrawal (n=4), or re-staging as low-risk MDS 
(n=1). Twenty patients continued AZA for a median of 7 cycles (range 5-12).  
Fifty-four patients (56%) received an allogeneic HSCT, after a median of 5 cycles of AZA 
(range 1-11 cycles), and 6.4 months (range 4.2- 14.3 months) from study inclusion. One 
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patient underwent HSCT in SD after only one AZA cycle due to a medical decision. 
Feasibility of HSCT reached 74% when the analysis was restricted to the 73 patients with 
a suitable donor.  
At the time of HSCT, 24 of the 54 patients were in CR (44.4%), 8 in PR (14.8%), 5 had HI 
(9.3%), 17 SD (31.5%). Compared to baseline, the HCT-CI re-evaluated prior to HSCT in 
52 patients with available data indicated that 5 of 24 patients with low-HCT progressed to 
intermediate or high HCT-CI (21%), while 5 of 6 patients with high HCT-CI at baseline 
remained stable (Supplementary Table 2). In 22 patients classified as intermediate HCT-CI 
at baseline, 7 patients improved to low and 7 progressed to high HCT-CI (p=0.3). This 
translated into worsening of comorbidities in 22% and improvement in 15% of patients 
after AZA “bridge”.  
Myeloablative and reduced intensity conditioning regimen was used in 28 and 26 patients, 
respectively. Donors were HLA-identical siblings in 16 patients (29.6%), MUD in 36 
(66.7%), and haplo-identical siblings in 2 patients (3.7%). Although haplo-identical sibling 
transplantation was not foreseen by the protocol, we included these two patients in the 
analysis, according to the primary objective of the study, which was feasibility of HSCT. 
Stem cell source was mostly peripheral blood (n=40, 74.1%) and the remaining bone 
marrow (n=14, 25.9%). Median time to engraftment was 18 days (range 10-43 days) for 
neutrophils, and 17 days (9-186 days) for platelets.  
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Survival analysis 
Median follow-up for surviving patients was 20.5 months (range 1.6-40.6). Median OS was 
15.2 months on an intent-to-treat (ITT) basis (n=97 patients, Supplementary Figure 1A). 
HSCT considered as a time-dependent covariate was associated to significantly longer 
survival in patients who received HSCT (median OS 20.9 months; range: 6.8-40.6) 
compared with those who did not receiving HSCT (median OS 9.4 months; range: 0.23-
21.3) (p=0.01, HR 041, 95% C.I. 0.22-0.78).  
At univariate analysis, significant prognostic factors for OS were very-high WPSS risk, high 
HCT-CI, and treatment response (Table 1 and Figure 2A and 2B). Multivariate analysis, 
including HSCT as time-dependent covariate, confirmed AZA treatment response as the 
only independent prognostic factor for OS. Treatment response and low HCT-CI were 
prognostic factors for PFS (Table 1, Supplementary figure 1B, Figure 2C).  
In the 54 patients who underwent HSCT, OS was not associated to status at HSCT 
(CR/PR/HI, versus SD, p=0.28), nor to IPSS-R at diagnosis (IPSS-R low vs Intermediate, 
vs high, vs very high, n=33 pts, p=0.492, Figure 3A-B). Low HCT-CI3 at the time of 
transplant remained a statistically significant prognostic factor for OS (n=52 patients, High 
vs Low: p=0.09, HR: 4.33, 95%CI: 1.63-11.51; Intermediate vs Low: p=0.007, HR: 3.81, 
95%CI: 1.45-10.00, Figure 3C). 
 
Adverse events and causes of death 
 
Sixty-four grade III-IV serious adverse events (SAEs) were reported in 58 patients. 
Adverse events were the cause of AZA discontinuation in 6 patients, and consisted of 
infections (4 pts), or hemorragic disorders (2 pts). SAE impeded HSCT in 3 patients, and 
consisted on an infection in 2 cases and an intra-abdominal hemorrage in 1 patient. Acute 
grade III-IV graft versus host disease (GVHD) was diagnosed in 3 patients (6%), while 
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chronic GVHD occurred in 14 patients (29%). At a median follow-up of 20.5 months from 
treatment start, 52 patients died. Causes of death in the non-HSCT group were disease 
progression or relapse (16 of 26 patients, 61.5%), followed by infectious (7 patients) and 
hemorrhagic complications (3 patients).  
In 54 patients undergoing HSCT, median survival after transplantation was 13.6 months. 
Mortality was transplant-related in 16 patients (30%, GVHD: 4 patients, infectious 
complication: 6 patients, multi-organ failure: 4 patients, other causes: 2 patients), disease 
relapse in 9 patients (17%), and a second malignant disease in 1 patient.  
 
DISCUSSION 
 
In this prospective study, we show that HSCT is feasible after AZA “bridge” in 74% of 
patients with HR-MDS or low-blast count AML with a suitable HSC donor. The trial 
included a population of patients with a median age of 59 years, with >10% bone-marrow 
blasts at protocol inclusion in 73% of cases, and adverse karyotype in 55%, which are 
negative prognostic factors for HSCT outcome in MDS.4,5,17 In the context of a close 
collaboration between MDS teams and HSCT units, AZA induced responses in 49% of our 
patients, considering together CR, PR or HI.  
Duration of response after AZA treatment is relatively short, of about 13-17 months, while 
HSCT is the only curative option in MDS.13,14,18 This has been recently confirmed by a 
prospective observational study conducted in France, where patients with an HLA-
matched donor had a significantly better 4-year OS, compared to those without a donor 
(37% vs 15%).19 Most of the patients in that study (76%) had received hypomethylating 
treatment prior to HSCT.                                                           
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It has been shown that best outcomes of HSCT in MDS rely on a shorter interval between 
diagnosis and transplantation.20 In our study, we identified a donor in 78% of patients, at a 
median of 3 months from protocol inclusion. The rapid identification of a HSC donor today 
may favor the applicability of upfront HSCT without any prior treatment in HR-MDS. In our 
study, AZA responders had a significantly longer survival than non-responders, reaching a 
median survival of over 2 years in patients who achieved CR or PR. Different from a recent 
report from Yahng et al.21, prolonged survival in our patients was not limited to patients 
achieving remission or HI, but was also observed in patients with SD, accounting for 29% 
of cases in our series. SD may also reflect a biologically less aggressive disease, 
independent from treatment, which would need to be characterized at initial diagnosis, 
most probably by identification of somatic mutations predictive not only of response, but 
also of SD after HMT.22-24  
In our series, AZA did not significantly affect patients’ comorbidities at HSCT. These data 
compare favorably to results of conventional chemotherapy schedules in HR-MDS. After 
HSCT, grade III-IV acute GVHD was rarely reported (6%), while grade III-IV chronic GVHD 
occurred in 29% of patients, similar to recent reports on HSCT preceded by HMT.19  In this 
line, AZA administered as maintenance after HSCT has been shown to increase the 
number of T regulatory cells and of cytotoxic T-cells, as mechanisms likely to increase the 
graft vs leukemia effect, without a concomitant increase in GVHD.25 Probably, changes 
related to AZA pretransplant do not play a significant role in post-transplant immunological 
changes.  
Our study, in the setting of patients with MDS, “highly eligible for transplant”, previously 
untreated, of a maximum age of 66, shows that HSCT is feasible in 74% of patients 
following AZA “bridge”, at a significantly higher rate than conventional chemotherapy in 
this setting. The major limitation of the study is that it does not answer the question 
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whether the patients who did not proceed to HSCT due to an adverse event (13%) or 
progressed during AZA (20%) could have benefited from upfront HSCT. This issue could 
be addressed by a prospective randomized study where upfront HSCT would be tested 
against HSCT after AZA. A major challenge for this type of study is heterogeneity of MDS, 
whereby karyotype and blast proportion, together with patient-related factors, as age and 
comorbidities, should be considered for adequate patient stratification.  
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FIGURE LEGENDS 
 
Figure 1  
Consort diagram 
 
Figure 2 
Survival Outcomes 
A) Overall Survival by response to AZA (n=87 patients) and B) by HCT-CI (n=97 
patients, months from AZA treatment start)  
C) Progression-free survival by response to AZA (n=87 evaluable patients, months 
from AZA treatment start) 
HSCT considered as time-dependent covariate was associated with a significantly longer 
survival (p=0.01, HR 0.41, 95% CI: 0.22-0.788). Multivariate analysis showed that 
treatment response was the only independent prognostic factor for survival (p=0.0007) 
 
Figure 3  
Overall survival after HSCT  
A) by AZA response at HSCT (n=54 pts) 
B) by IPSS-R (n= 33 MDS pts) 
C) by HCT-CI (n=52 pts with available HCT-CI at the time of HSCT) 
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Table 1 Prognostic factors for survival outcomes 
  
  Overall Survival 
Progression-Free 
Survival 
Non-Relapse Mortality 
HR (95%CI) p 
HR  
(95%CI) 
p 
HR  
(95%CI) 
p 
Age <50 vs >51 
years 
0.53  
(0.24-1.17) 
0.118 
0.59  
(0.29-1.19) 
0.140 
0.58  
(0.20-1.67) 
0.310 
BM-Blasts  
(below or over 
10%) 
0.54  
(0.25-1.17) 
0.118 
0.55  
(0.27-1.10) 
0.090 
0.54  
(0.25-1.17) 
0.118 
IPSS  
(High vs Int-2) 
1.62  
(0.82-3.19) 
0.162 
1.28  
(0.68-2.43) 
0.440 
1.69  
(0.64-4.46) 
0.287 
WPSS  
(High vs V-High) 
0.39  
(0.19-0.84) 
0.015 
0.53  
(0.27-1.05) 
0.067 
0.60  
(0.21-1.72) 
0.342 
WPSS  
(Intermediate vs 
V-High) 
0.34  
(0.12-0.97) 
0.044 
0.49  
(0.19-1.26) 
0.137 
0.35  
(0.07-1.77) 
0.206 
IPSS-R  
(High vs V-High) 
0.53  
(0.21-1.33) 
0.177 
0.72  
(0.33-1.58) 
0.416 
0.62  
(0.19-1.96) 
0.420 
IPSS-R  
(Intermediate vs 
V-High) 
0.96  
(0.33-2.85) 
0.949 
1.20  
(0.45-3.21) 
0.718 
0.46  
(0.06-3.57) 
0.458 
HCT-CI   
(High vs Low) 
2.91  
(1.22-6.97) 
0.016 
2.10  
(0.92-4.78) 
0.076 
1.88 (0.50-
7.10) 
0.352 
HCT-CI High vs 
Intermediate 
2.67  
(1.41-5.04) 
0.002 
2.19  
(1.25-3.82) 
0.006 
2.45  
(1.05-5.74) 
0.040 
CR/PR/HI/mCR 
vs PD 
0.22  
(0.09-0.50) 
0.0001 
0.03  
(0.01-0.08) 
<.0001 
0.13  
(0.05-0.35) 
<.0001 
SD vs PD 
0.38  
(0.16-0.88) 
0.024 
0.06  
(0.02-0.14) 
<.0001 
0.14  
(0.04-0.48) 
0.0007 
Ferritin (as 
continuous 
variable) 
1  
(0.99-1.00) 
0.526 
1  
(0.99-1.00) 
0.648 
1.00  
(0.99-1.00) 
0.322 
HLA-id vs MUD 
(n=54) 
0.50  
(0.20-1.28) 
0.149 
0.45  
(0.18-1.14) 
0.093 
0.57  
(0.15-2.17) 
0.412 
Myeloablative vs 
RIC (n=54) 
0.6  
(0.27-1.32) 
0.205 
0.67  
(0.32-1.42) 
0.296 
1.06  
(0.32-3.48) 
0.920 
 
 
Supplementary Material 
BMT-AZA Protocol eligibility criteria 
Patients were eligible if they had a diagnosis of IPSS intermediate-2 or high-risk MDS, 
RAEB-t (at present classified as AML with 20-30% blasts, here defined as low-blast count 
AML), or CMML-2, with 10-29% bone marrow (BM) or peripheral blood (PB) blasts, and 
WBC < 20 x 109/L. Other inclusion criteria were age between 18 and 65 years, Eastern 
Cooperative Oncology Group (ECOG) performance status less than 3, and life expectancy 
of over 3 months.  
A donor search activation was mandatory at the time of protocol enrolment. Patients with 
severe organ impairment or active viral infections were not included in the trial. Patients 
who had received prior HMT, chemotherapy or radiotherapy during the last 6 months, 
investigational drugs during the last 30 days or hematopoietic growth factors during the 
last 21 days were also excluded. 
 
 
Statistical Analysis 
This study was designed as a Simon optimal two-Stage Phase II clinical trial19 to test the 
null hypothesis that P<0.180 versus the alternative that P>0.300 had an expected sample 
size of 50.78 and a probability of early termination of 0.681.  
After testing the treatment on 31 patients in the first stage (interim analysis), the trial would 
have been terminated if 6 or fewer had achieved the primary end-point, i.e. HSCT. If more 
than 6 patients underwent HSCT, then the trial would proceed to the second stage, and a 
total of 93 patients would have to be enrolled. If the total number of patients undergoing 
HSCT were less than or equal to 22, the study would have failed to reach the primary end-
point.  
 
Baseline patient characteristics, disease history, and treatment-related variables were 
summarized using descriptive summary statistics and graphical approaches. Differences in 
the distribution of prognostic factors in patient subgroups were analyzed by the Chi-square 
or Fisher’s exact test and by the Wilcoxon test. PFS and OS were calculated using the 
Kaplan-Meier method. PFS was the time between the first dose of AZA and disease 
progression to AML in higher-risk MDS, and date of relapse in AML, or of death, whichever 
was first reported. Secondary endpoints are presented along with 95% confidence 
intervals for each stratum separately.  
Differences in survival were calculated by the log rank test in univariate analysis and by 
the Cox regression model in multivariate analysis. The Cox proportional hazard regression 
model was used to examine the risk factors affecting time to event. All statistical analyses 
were performed using the statistical software SAS (release 9.4). 
Supplementary Table 1 
Patient Characteristics (n=97 patients) 
Age (median, range) 59 (21-66) 
Disease duration (months, median, range) 0.9 (0-105) 
BM-blasts % (median, range) 15 (0-30) 
Blood counts 
(median, range) 
Hb (g/dl) 
Neutrophils (109/L) 
Platelets (109/L) 
9.3 (6.5-13.3) 
0.7 (0.1-41) 
74 (6-662) 
ECOG (n) 
0 
1 
2 
70 (72%) 
17 (17.5%) 
10 (10%) 
WHO 2016 
Classification (n) 
MDS-SLD/MLD 
MDS-EB-1 
MDS-EB-2 
AML (20-30% blasts) 
CMML-2 
8 (8%) 
11 (11%) 
51 (53%) 
19 (20%) 
8 (8%) 
Karyotype 
(n=87) 
Normal 
Trisomy 8 
-7 
Del 5q 
Other monosomies 
Complex (>3 abn) 
Other 
32 (37%) 
4 (4.5%) 
13 (15%) 
3 (3.5%) 
3 (3.5%) 
23 (26.5%) 
9 (10%) 
IPSS (n=87) 
Low/Int-1 
Int-2 
High 
3 (3.5%) 
43 (49.5%) 
41 (47%) 
WPSS (n=69) 
Low/Interm. 
High 
Very high 
9 (13%) 
42 (61%) 
18 (26%) 
R-IPSS 
(n=69) 
Very low/low 
Intermediate 
High 
Very high 
4 (6%) 
11 (16%) 
21 (30%) 
33 (48%) 
HCT-CI 
(n=97) 
Low (0) 
Intermediate (1-2) 
High (>3) 
46 (47%) 
41 (42%) 
10 (10%) 
Ferritin (ng/mL, 
median, range) 
214 (1-909) 
 2
 
Supplementary Table 2: 
Changes in patients’ HCT-CI from baseline to HSCT 
(n=52 patients with available HCT-CI at HSCT) 
 
HCT-CI at Baseline 
HCT-CI at HSCT 
Low (0) Intermediate 
(1-2) 
High (>3) Total 
Low (0) 19 4 1 24 
Intermediate (1-2) 7 8 7 22 
High (>3) 0 1 5 6 
Total 26 13 13 52 
*p=0.3 
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